This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Viatris (VTRS) to Divest Some More Businesses, Shares Gain
by Zacks Equity Research
Viatris (VTRS) enters into agreements to divest its remaining businesses previously planned for 2023. Its shareholders are upbeat about the same.
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent
by Zacks Equity Research
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids
by Zacks Equity Research
Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.
Company News for Aug 8, 2023
by Zacks Equity Research
Companies in The News Are: KKR,SAGE,VTRS,FRPT
Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows
by Zacks Equity Research
Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance.
Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q2 results are likely to be impacted by foreign exchange rates. Nevertheless, momentum in the branded business is likely to have continued.
Viatris (VTRS) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.85, making no change from the previous trading session.
Why Is Viatris (VTRS) Down 2.4% Since Last Earnings Report?
by Zacks Equity Research
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Viatris (VTRS) Tops Q1 Earnings Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 13.04% and 1.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.
Bausch + Lomb (BLCO) Q1 Earnings Lag Estimates
by Zacks Equity Research
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.36, moving +0.32% from the previous trading session.
Icon PLC (ICLR) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Icon PLC (ICLR) delivered earnings and revenue surprises of -2.68% and 0.35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Highlights Humana, Viatris, agilon health and Cano Health
by Zacks Equity Research
Humana, Viatris, agilon health and Cano Health are included in this Analyst Blog.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Viatris (VTRS) closed the most recent trading day at $9.18, moving -1.61% from the previous trading session.